Kni 102

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H341043

CAS#: 139694-65-8

Description: Kni 102 is a biochemical.

Chemical Structure

img
Kni 102
CAS# 139694-65-8
Instruction

Theoretical Analysis

Hodoodo Cat#: H341043
Name: Kni 102
CAS#: 139694-65-8
Chemical Formula: C31H41N5O7
Exact Mass: 595.30
Molecular Weight: 595.697
Elemental Analysis: C, 62.51; H, 6.94; N, 11.76; O, 18.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Kni 102; Kni-102; Kn102.

IUPAC/Chemical Name: L-Prolinamide, N2-((phenylmethoxy)carbonyl)-L-asparaginyl-(2S,3S)-2-hydroxy-4-phenyl-3-aminobutanoyl-N-(1,1-dimethylethyl)-

InChi Key: XCVUOCMQYKSJJR-IGRGDXOOSA-N

InChi Code: InChI=1S/C31H41N5O7/c1-31(2,3)35-28(40)24-15-10-16-36(24)29(41)26(38)22(17-20-11-6-4-7-12-20)33-27(39)23(18-25(32)37)34-30(42)43-19-21-13-8-5-9-14-21/h4-9,11-14,22-24,26,38H,10,15-19H2,1-3H3,(H2,32,37)(H,33,39)(H,34,42)(H,35,40)/t22-,23-,24-,26-/m0/s1

SMILES Code: C1CC[C@H](N1C([C@H]([C@@H](NC(=O)[C@@H](NC(OCc1ccccc1)=O)CC(N)=O)Cc1ccccc1)O)=O)C(NC(C)(C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 595.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Asagarasu A, Takayanagi N, Achiwa K. Synthesis of dipeptide-type human immunodeficiency virus (HIV) protease inhibitors with a binding unit to gp120. Chem Pharm Bull (Tokyo). 1998 May;46(5):867-70. PubMed PMID: 9621421.

2: Asagarasu A, Uchiyama T, Achiwa K. Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):697-703. PubMed PMID: 9579045.

3: Marastoni M, Fantin G, Bortolotti F, Tomatis R. Synthesis and activity of pseudotripeptide inhibitors of HIV-1 protease containing D(-)-O-(benzyl)tartaric acid. Arzneimittelforschung. 1996 Nov;46(11):1099-101. PubMed PMID: 8955873.

4: el-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, Hatanaka M, Harada S. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol. 1994 Jan;68(1):233-9. PubMed PMID: 8254733; PubMed Central PMCID: PMC236282.

5: Kato R, Takahashi O, Kiso Y, Moriguchi I, Hirono S. Solution structure of HIV-1 protease-allophenylnorstatine derivative inhibitor complex obtained from molecular dynamics simulation. Chem Pharm Bull (Tokyo). 1994 Jan;42(1):176-8. PubMed PMID: 8124761.

6: Fujisawa Y, Kakinuma A. [HIV protease inhibitors]. Tanpakushitsu Kakusan Koso. 1993 Aug;38(11):2012-30. Review. Japanese. PubMed PMID: 8210441.

7: Mimoto T, Imai J, Tanaka S, Hattori N, Kisanuki S, Akaji K, Kiso Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):3088-90. PubMed PMID: 1799953.